Cambridge Healthtech Institute’s 5th Annual

Point-of-Care Diagnostics

Disrupting Healthcare Delivery

20-21 May 2020

Point-of-care diagnostics is one of the fastest moving segments of the diagnostics market, and innovations in sensors, microfluidics and smartphone technologies are allowing faster and more accurate diagnosis and monitoring of disease. The Fifth Annual Point-of-Care Diagnostics: Disrupting Healthcare Delivery conference in Lisbon will feature the latest technologies and trends in rapid testing for healthcare settings, and will bring new infectious disease, antimicrobial stewardship, rare cell and CRISPR-Cas9 detection for application around the world. Point-of-care testing is being developed for a variety of settings including field applications, doctors' offices or at home. Please join us to hear about the latest platforms, features, and progress.

Final Agenda



11:00 Registration

11:35 Breakout Discussions (Visit for details)

12:35 Session Break


14:00 Keynote Introduction

Gyorgy Abel, MD, PhD, Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Laboratory Medicine, Lahey Hospital & Medical Center, United States


14:05 Rapid AMR Detection and Rapid Antimicrobial Susceptibility Testing – Two Sides of the Same Coin in the Fight against AMR?

Till T. Bachmann, PhD, Professor, Deputy Head, Division of Infection and Pathway Medicine, Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, United Kingdom

Rapid diagnostics is considered a key tool to tackle antimicrobial resistance. While rapid molecular diagnostics of pathogens and antimicrobial resistance is established as a strong contender of traditional culture-based pathogen identification and susceptibility testing, its strengths lie in the determination of which antibiotics to avoid. Rapid antimicrobial susceptibility testing to find out which antibiotic to use is emerging at rapid pace using innovative techniques for phenotypic testing. The presentation will discuss the current landscape and emerging opportunities of these two leading diagnostic perspectives.

14:35 The Longitude Prize: Overcoming Hurdles to Market for AMR Point-of-Care Diagnostics

Caroline Purslow, Global Health Programme Manager, Nesta Challenges, United Kingdom

Use of point-of-care diagnostic tests would reduce the overuse and misuse of antibiotics. Innovation in this area is moving at a rapid pace, yet few of these products have reached clinicians. The Longitude Prize was created to stimulate this innovation, yet without removing barriers to market access and implementation, a winning test cannot have the desired impact. This talk will provide an update on the Longitude Prize portfolio and the steps the project and wider community are undertaking to ensure novel point-of-care diagnostics reach the front line.

15:05 Chest Infection: Are You Sure You Need Those Antibiotics?

Liz Cross, Advanced Nurse Practitioner, QN, Attenborough Surgery, Bushey Medical Centre, Herts Valleys Clinical Commissioning Group, NIHR, United Kingdom

The outlying 5 highest antibiotic-prescribing practices within Hert Valley CCG were selected and offered C-reactive protein (CRP) point-of-care-testing (POCT) as an intervention to aid them to reduce their antibiotic prescribing. These practices were provided with CRP machines for a one-year period, along with education. A practice champion in each surgery was identified who helped staff to engage with using the CRP POCT machine and who could help with identified problems, especially in the early stages. CRP POCT was not offered to every patient, just those cases where the GP had some reservations about the need for a prescription. The results show that 81% of patients offered CRP POCT did not receive antibiotics and 92% of patients did not reattend the practice within 28 days after having received a CRP POCT. We believe that if CRP POCT was not available then the majority of these patients would have been prescribed antibiotics. CRP POCT has therefore proven to be a beneficial tool in these high prescribing practices to reduced unscheduled reattendances and supporting GPs to use antibiotics more effectively.

15:35 Sponsored Presentation (Opportunity Available)

16:05 Refreshment Break in the Exhibit Hall with Poster Viewing


17:00 Chairperson’s Remarks

Gyorgy Abel, MD, PhD, Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Laboratory Medicine, Lahey Hospital & Medical Center, United States

17:05 Three Novel Point-of-Care (POC) Platforms for Molecular Pathogen Testing Based on Real-Time PCR, Digital Single-Cell RPA, and Electrochemical LAMP

Apl. Prof. Dr. Felix von Stetten, Associate Director, Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., Germany

Three POC platforms of different technology-readiness-levels (TRLs) are presented: 1) The Spindiag platform (TRL-6), performing real-time PCR-based admission screening for antibiotic-resistant bacteria (MRSA, CRO, VRE); 2) a digital sample-to-answer-platform (TRL-4) for the massively parallel analysis of single MRSA/MSSA cells for species and resistance gene; and 3) a miniaturized electrochemical platform for isothermal amplification (TRL-3) using real-time mediator displacement LAMP, recently validated with HIV-1 and HTLV-1.

17:35 Point-of-Care Diagnostic and Monitoring of Bacterial Infections

Winnie Edith Svendsen, PhD, Professor, Department of Biotechnology and Biomedicine Section for Microbial and Chemical Ecology, Technical University of Denmark, Lyngby, Denmark

The challenges of introducing point-of-care detection of bacterial-specific infections are plentiful. In this talk, I will discuss three examples with different challenges of bacterial infections and the technology applied to solve these challenges. I will illustrate how quorum sensing can be used to fingerprint pseudomonas infection in the lungs of cystic fibrosis patients from sputum samples using electrochemical methods. I will discuss how electrochemical impedance spectroscopy can be used to monitor the correct dosing of the antibiotic, Vancomycin, which is toxic but a last resort antibiotic for treating resistant bacterial infections in humans. Finally, I will demonstrate a simple method to monitor if a bacterial contamination exists on surfaces, e.g. for hygiene control. I will discuss the challenges, encounters, pros and cons of each method for point-of-care detection.

18:05 The Case for Grassroots Innovation in POCT

Gyorgy Abel, MD, PhD, Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Laboratory Medicine, Lahey Hospital & Medical Center, United States

Dx innovation is commonly initiated at the top of the pyramid: major companies analyze trends, recognize unmet needs, and instruct their R&D departments to develop new or upgraded diagnostic systems. It generally works well for large, expensive platforms, but often falls short in POCT. The modest capital requirement for POCT development allows free-flowing, “outside the box” thinking and enables grassroots innovation at startups and academic incubators. Esoteric new ideas are welcome in grassroots, but often thwarted in corporate environments. Grassroots innovation has been a rich source of new POCT solutions as illustrated by examples in this presentation.

18:35 Close of Day




08:30 Registration and Morning Coffee

09:00 Chairperson’s Remarks

Becker_HolgerHolger Becker, PhD, Founder & CSO, microfluidic ChipShop GmbH, Germany

09:05 Energy-Efficient and Precise Photon-Based Technology for Optical Heating and Temperature Control in a Microfluidic System for Nucleic Acid Amplification at Point-of-Care

Miron Tokarski, CEO, Genomtec S.A., Poland

Currently, microfluidic systems for genetic testing are largely based on PCR technology. This approach has several problems linked with energy consumption, efficient heating and cooling, size and the high complexity of the diagnostic systems which result in limited access to genetic testing benefits. The Genomtec team has developed a unique LED-based heating system and contactless temperature detection system for use on INAAT assays in microfluidic point-of-care systems.

09:35 Automated Platform for Near-Patient, Rapid Microfluidic Extraction of Circulating Nucleic Acids from Milliliter Volumes of Whole Blood

Maïwenn Kersaudy-Kerhoas, PhD, Associate Professor, Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, United Kingdom

For extracellular plasma circulating cell-free nucleic acids (CNAs) to have an impact on healthcare, a key challenge to overcome is the development of rapid and reliable low-cost sample preparation. We demonstrate a microfluidic system able to perform the extraction of circulating cell-free miRNAs and DNA from several milliliters of whole blood in a single disposable fluidic cartridge, on a fully automated platform, delivering a stable elution of CNAs in under an hour.

10:05 Sponsored Presentation (Opportunity Available)

10:35 Coffee Break in the Exhibit Hall. Last Chance for Poster Viewing

11:20 CRISPR-Powered Electrochemical Nucleic Acid Diagnostics

Dincer_CanCan Dincer, PhD, Junior Research Group Leader, Freiburg Center for Interactive Materials and Bioinspired Technologies (FIT) and Department of Microsystems Engineering (IMTEK), University of Freiburg, Germany

Nucleic acid testing is decisive for the diagnosis of many diseases in medicine. Besides its wide application in gene editing, CRISPR technology features a powerful tool for the highly sensitive and selective quantification of nucleic acids. In this talk, the first CRISPR/Cas13a powered electrochemical microfluidic biosensor for on-site miRNA detection will be presented. Without any target amplification, it offers a low-cost, easily scalable, and multiplexed approach for nucleic acid diagnostics.

11:50 KEYNOTE PRESENTATION: Molecular POCT: From Esoteric to Mainstream – From Concept to Production

Anders Wolff, PhD, Professor, Department of Biotechnology and Biomedicine, Technical University of Denmark, Denmark

Far too many point-of-care tests (POCT) developed at universities are never commercialised. For commercialisation, it is important to consider the choice of materials, fabrication-, bonding-, and detection methods, etc. These should be suitable for mass production, low cost and easy to use and handle. In my group, we have developed different solutions, design and methods that can be produced at a realistic low price and can be scaled up from prototypes to full-scale industrial mass production. Other important issues are assay design and integrated reagents. I will discuss these subjects and include examples from our research.

12:20 Sponsored Presentation (Opportunity Available)

12:50 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

13:20 Session Break


13:50 Chairperson’s Remarks

Vincent Linder, PhD, CEO, Calciscon, Switzerland; Founder and President, CDP BioMedical Consulting, Portugal

14:00 Nanodroplet Microfluidics – A Versatile Tool for Continuous Biomarker Monitoring: Case Study of a Wearable Sensor for Lactate Monitoring

Oliver Hofmann, PhD, MBA, CEO, SouthWestSensor Limited, United Kingdom

Nanodroplet microfluidics provides a powerful tool for high-frequency, wet chemistry-based measurement of biomarkers. We describe the transition of this versatile approach from lab to point-of-care use. SouthWestSensor Ltd. has developed a wearable sensor solution for measuring lactate, a key marker for instance in the management of sepsis. We demonstrate tracking of lactate levels in dermal tissue with results in close agreement with off-line analysis of peripheral blood samples.

14:30 Development and Clinical Validation of the T50 Test for Accurate Measurement of Phosphate Toxicity, and Its Extension to the Point-of-Care

Vincent Linder, PhD, CEO, Calciscon, Switzerland; Founder and President, CDP BioMedical Consulting, Portugal

Calciscon has developed the T50, a blood test for Phosphate Toxicity, which is the adverse effect that phosphate exerts on cells, tissues and organs, and is associated with numerous pathologies. In this contribution we discuss the foundational work that led to the invention of the T50, its clinical validation across multiple cohorts of patients with chronic kidney diseases (CKD), and the adaptation of the test to deliver clinical value in point-of-care applications.

15:00 Ultra-Fast, Highly Multiplexed Point-of-Care Test for Detection of MSSA/MRSA/PVL within 15 Minutes from a Nasal Swab to Results

Piotr Garstecki, PhD, President & CTO, Scope Fluidics SA, Poland

We use the PCR|ONE point-of-care molecular diagnostics platform in screening tests detecting MSSA, MRSA and the gene coding the PVL toxin. We describe the technical realization of key stages of the protocol, including automated sample preparation and DNA isolation, microfluidic multiplexing and infrared radiation-mediated ultra-fast PCR reaction, together with the results of validation in clinical environment.

15:30 Biowatch and What Home Dx and Wearable IVD Products Can Do Outside of Healthcare

Mikkel Thykjær Jørgensen, CEO, Founder & Partner, Biowatch ApS, Denmark

Biowatch gives health-interested users access to professional analysis of biological material, enabling the user to detect and correct imbalances, optimize performance, and proactively engage in the prevention of lifestyle diseases.

16:00 Close of Conference

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag


19-20 MAY 2020

20-21 MAY 2020